BioNTech SE (NASDAQ: BNTX) reported Q4 EPS of EUR12.18. Revenue for the quarter came in at EUR5.53 billion.

Estimated BioNTech COVID-19 vaccine revenues for the full 2022 financial year €13 billion - €17 billion

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.